"But we remain confident in the longer-term potential of the medicine in the IV form to reach ultimately USD 2 billion. It remains the treatment of choice for newly diagnosed patients. We're seeing about 15% of patients in the EU in the older than 2 year age range. We're on our way to get access in 9 EU countries, which would be about 25% of the population. And we have important formal reimbursement decisions in 15 countries over the coming year to 2 years. So taken together, we think we're on the right track."